Evonik, one of the world's leading specialty chemicals companies, conducted a seminar in Cairo yesterday with more than 150 members of the Egyptian pharmaceutical industry to support increasing demand for local production of medicines.
The seminar in Cairo provided an opportunity to inform Egyptian lab managers, senior scientists and other local pharmaceutical leaders about the latest trends and opportunities in the use of EUDRAGIT® polymers for the development of high-quality drug formulations.
“The seminar we held in Cairo back in January 2015 was a great success. But the event yesterday surpassed our greatest expectations for attendance and customer interest” said Feras Melhem, Health Care Business Manager for the Middle East and North Africa at Evonik.
“Egypt is rapidly becoming one of the largest and most important markets in the Middle East and North Africa region. This progression is largely due to governmental efforts to increase local production so that vital medicines are available to Egyptians at a cheaper price” Melhem added.
Evonik Health Care has been a formulation development partner and supplier of drug substances and functional excipients to the Egyptian healthcare sector for more than four decades through local partners. Its flagship EUDRAGIT® portfolio has continuously lived up to its reputation as the gold-standard for functional coatings for oral solid dosage forms.
The event took place at Fairmont Heliopolis Hotel.
Evonik is one of the world leaders in specialty chemicals. The focus on more specialty businesses, customer-orientated innovative prowess and a trustful and performance-oriented corporate culture form the heart of Evonik’s corporate strategy. They are the lever for profitable growth and a sustained increase in the value of the company. Evonik benefits specifically from its customer proximity and leading market positions. Evonik is active in over 100 countries around the world with more than 35,000 employees. In fiscal 2016, the enterprise generated sales of around €12.7 billion and an operating profit (adjusted EBITDA) of about €2.165 billion.